Disc Medicine

Disc Medicine EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Disc Medicine (IRON) as of Nov 21, 2026 is -236.02 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -129.72 M USD — a change of 81.95% (lower).

EBITDA

-236.02 MUSD

YoY

81.95%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Disc Medicine is 2025 -236.02 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Disc Medicine was 2024 -129.72 M USD. It decreases by 81.95% lower compared to the previous year.

The Disc Medicine EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
0.00 USD
Jan 1, 2020
-34.04 M USD
Jan 1, 2021
-30.93 M USD
Jan 1, 2022
-47.48 M USD
Jan 1, 2023
-91.13 M USD
Jan 1, 2024
-129.72 M USD
Jan 1, 2025
-236.02 M USD
The Disc Medicine EBITDA history
YEAREBITDAYoY
-236.02 MUSD+81.95%
-129.72 MUSD+42.35%
-91.13 MUSD+91.94%
-47.48 MUSD+53.48%
-30.93 MUSD-9.13%
-34.04 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Disc Medicine Stock analysis

What does Disc Medicine do? Disc Medicine, Inc. generates revenue through the development and commercialization of therapeutic candidates targeting hematologic diseases. The company's pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria and X-linked protoporphyria, DISC-0974 for anemia of myelofibrosis and chronic kidney disease, and MWTX-003 for polycythemia vera. These products are developed to address fundamental biological pathways in red blood cell biology, focusing on heme biosynthesis and iron homeostasis. The company's target segments include patients suffering from serious hematologic conditions requiring novel treatments. Disc Medicine's preclinical program DISC-0998 targets anemia associated with inflammatory diseases, expanding its portfolio for future commercialization. The company's primary focus on discovering and developing treatments for hematologic diseases positions it to serve patients with unmet medical needs in these areas. Revenue streams are expected to emerge from the successful development and approval of these therapeutic candidates by regulatory authorities. The company builds its portfolio around targeting red blood cell biology pathways, with bitopertin, DISC-0974, and MWTX-003 representing key products in clinical development. These products are designed to address specific hematologic disorders, including Diamond-Blackfan Anemia and anemia of myelofibrosis, which are currently underserved in the market. Disc Medicine's business model relies on the progression of these candidates through clinical trials and eventual market entry. Disc Medicine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Disc Medicine stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Disc Medicine is -236.02 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Disc Medicine changed from -129.72 M USD to -236.02 M USD, representing a 81.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Disc Medicine since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Disc Medicine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Disc Medicine

All Key Metrics — Disc Medicine